🔗 Share this article

As America continues making sweeping changes to its immunization guidelines, a particular individual appears unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 vaccines in the pandemic and has zeroed in on alleged deaths following COVID-19 immunization in her short tenure at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Schedule

Public health authorities planned to announce sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would place the US at odds with a large portion of the global community with little proof for benefit. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

A New Direction at the FDA

This interim role might represent a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has repeatedly called for discontinuing some childhood shot schedules in the US so as to align more like the Danish model, a nation with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent track record in drug development, oversight or administrative roles, which has been customary for former heads of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a large organization. She lacks background in drug approvals.”

Former heads of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that previous people who ran the center have had.”

This division has an immense range of responsibilities at the agency, she stated.

“The public just focuses on the novel medication approvals, but the generic program authorizes numerous off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those have to be managed,” Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial leadership aspect to the position, which manages more than 5,000 personnel. “It’s a huge administrative position, if you perform it correctly,” she said.

Response and Disputed Policies

Regarding questions about Høeg’s fitness for the role and whether this selection represents greater collaboration among regulatory chiefs on vaccines, a representative responded that the “inquiries stem from incorrect assumptions”.

“Her experience matches the functions of her role,” the representative stated, noting the time Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a contentious rapid drug-approval program that allegedly concerned her former heads. “By what process are these therapies being chosen for this voucher program? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the FDA seems to be moving towards more relaxed rules of all drugs, except for shots.”

Public Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if problematic, past, some experts observe. She authored a research paper using unconfirmed public submissions to assess the frequency of myocarditis after COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the incoming government included changing guidelines for new vaccines and discontinuing “optional” vaccines, she stated following the vote on a audio program. At the FDA, Høeg has reportedly floated the idea of barring adolescent males from obtaining COVID-19 vaccines.

“She is an thorough ideologue who commences with her preconceived notions and works backwards to retrofit the science in a very misleading, untruthful way,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|